Therefore, soluble NKG2DLs levels are expected to be markers of tumor progression and prognosis, because soluble MICA and ULBP-2 levels distinguish significantly between benign and malignant disease, both in solid organ cancers and in hematopoietic cancers (22, 31). Here, ULBP2 is linked to hematopoietic and lymphoid cell neoplasm.